Saluda Medical logo

Saluda Medical Pty Ltd

Healthcare

Saluda Medical Stock

Saluda Medical is a leader in neuromodulation therapy, dedicated to transforming chronic pain management. By focusing on advanced spinal cord stimulation technologies, the company provides innovative solutions that adapt in real-time to patients' needs. Saluda Medical's cutting-edge research and clinical trials support their commitment to improving patients' quality of life through precise and effective pain relief methodologies.

Founded: 2013

Saluda Medical Website

Saluda Medical Company Overview

Saluda Medical specializes in advanced neuromodulation therapies. Their groundbreaking product, the Evoke® System, is the world's first closed-loop spinal cord stimulation (SCS) system that measures and responds to the spinal cord’s electrical activity. Utilizing Evoked Compound Action Potentials (ECAPs), the Evoke® System can automatically adjust stimulation parameters in real-time, ensuring optimal and consistent pain relief tailored to each patient’s needs. This adaptive technology can make up to four million adjustments per day, significantly enhancing the efficacy of chronic pain treatments. The company’s innovative approach is backed by over a decade of research and numerous clinical trials, including the pivotal EVOKE study. This study demonstrated the Evoke® System's superior outcomes compared to traditional SCS systems, highlighting its ability to provide sustained pain relief and improve the quality of life for patients. Saluda Medical's technologies are designed to maintain optimal stimulation levels by continuously adapting to the body’s physiological responses, a significant advancement over conventional methods that do not adjust in real-time. Led by a team of experienced professionals in the medical device and neuromodulation fields, Saluda Medical is committed to pushing the boundaries of chronic pain management. The company’s vision extends beyond spinal cord stimulation, with ongoing research into applications for other neuromodulation therapies such as vagal nerve, sacral nerve, and deep brain stimulation. This broader focus underscores their ambition to lead in multiple areas of neuromodulation therapy. Saluda Medical’s dedication to innovation and clinical excellence has positioned them as a leader in the neuromodulation industry. Their technologies offer not only effective pain relief but also the potential for significant improvements in overall patient well-being. By continually advancing their research and development efforts, Saluda Medical aims to provide cutting-edge solutions that transform the treatment of chronic pain and enhance the lives of patients worldwide.

Management Team

Jim Schuermann President and Chief Executive Officer
James Erickson Chief Financial Officer
Robert Gaffney Chief Operating Officer
Dan Brounstein Chief Strategy Officer
Peter Single Chief Technology Officer
Yolanda Blasing Chief Accounting Officer
Kristin Caplice Chief Legal Officer
Tim Benner Chief Commercial Officer
Steven McQuillan Chief Clinical and Regulatory Officer

Funding Information